AAGP (PKX-001) / ProtoKinetix - LARVOL DELTA

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: University of Alberta | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: University of Alberta | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: University of Alberta | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: University of Alberta | Trial completion date: Sep 2023 ➔ Sep 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: University of Alberta | Trial completion date: Jan 2023 ➔ Sep 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants (Businesswire) - "ProtoKinetix...today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants. The molecule, PKX-001 (AAGP®) successfully achieved, to date, the primary safety objectives. The trial is continuing with observation of the latest enrolled patients to monitor secondary objectives over the next 6-months. Following this period of follow-up, all secondary objectives will have been evaluated in all patients, and the data will be collated, analyzed, and reported....'We are excited to move forward with dose escalation in this exciting trial using this anti-aging glyopeptide molecule AAGP, and eagerly await data on how this might improve and protect islets after transplant. Certainly, at this point the data shows the molecule is safe.'"

Enrollment status • Immunology • Metabolic Disorders

Islet Transplantation Using PKX-001 (clinicaltrials.gov) - P1; N=6; Recruiting; Sponsor: University of Alberta; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX-001. (PubMed, J Tissue Eng Regen Med) - "Furthermore, optokinetic tracking and electroretinography responses in vivo were significantly improved compared to cell transplants without PKX-001 pre-treatment. These data demonstrate that PKX-001 promotes significant long-term stem cell survival in vivo, providing a platform for further investigation towards the clinical application to repair damaged or diseased retina."

Journal • Preclinical • CNS Disorders • Genetic Disorders • Inherited Retinal Dystrophy • Mood Disorders • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • Transplantation